Analyzing BR Biopharma (BRBI) & The Competition

BR Biopharma (NASDAQ:BRBI) is one of 1,748 public companies in the “Capital Markets” industry, but how does it compare to its competitors? We will compare BR Biopharma to similar businesses based on the strength of its institutional ownership, profitability, valuation, risk, earnings, dividends and analyst recommendations.

Dividends

BR Biopharma pays an annual dividend of $0.42 per share and has a dividend yield of 3.8%. BR Biopharma pays out 525.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Capital Markets” companies pay a dividend yield of 3.2% and pay out 30.8% of their earnings in the form of a dividend.

Profitability

This table compares BR Biopharma and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BR Biopharma	N/A	N/A	N/A
BR Biopharma Competitors	266.99%	77.99%	3.52%

Institutional and Insider Ownership

30.6% of shares of all “Capital Markets” companies are owned by institutional investors. 12.9% of shares of all “Capital Markets” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for BR Biopharma and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BR Biopharma	1	0	0	0	1.00
BR Biopharma Competitors	5372	19707	21893	613	2.37

As a group, “Capital Markets” companies have a potential upside of 27.48%. Given BR Biopharma’s competitors stronger consensus rating and higher probable upside, analysts plainly believe BR Biopharma has less favorable growth aspects than its competitors.

Valuation & Earnings

This table compares BR Biopharma and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BR Biopharma	$2.23 billion	$31.36 million	138.05
BR Biopharma Competitors	$2.22 billion	$396.25 million	8.85

BR Biopharma has higher revenue, but lower earnings than its competitors. BR Biopharma is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

BR Biopharma competitors beat BR Biopharma on 11 of the 14 factors compared.

BR Biopharma Company Profile

BRBI BR Partners S.A., through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners S.A. is based in S?o Paulo, Brazil.